StemCells, Inc. (NASDAQCM: STEM) is a biopharmaceutical company engaged in the research, development and commercialization of stem cell therapeutics and related tools and technologies for application to stem cell-based research and drug discovery and development. The company develops HuCNS-SC cells that have completed Phase I clinical trial in pelizaeus-merzbacher disease, a fatal myelination disorder in brain; completed a Phase I clinical trial in infantile and late infantile neuronal ceroid lipofuscinosis, which is a neurodegenerative disorder of the brain. StemCells is also conducting preclinical studies in Alzheimer’s disease. For more information, visit the company’s website at www.stemcellsinc.com.